AccurKardia wins Best New Tech Solution for ECG at MedTech Breakthrough Awards

AccurKardia’s ECG analysis platform, AccurECG, has been named “Best New Technology Solution for ECG” in the 9th annual MedTech Breakthrough Awards, the company announced.

The MedTech Breakthrough Awards, run by independent market intelligence group MedTech Breakthrough, recognize top innovations in the global digital health and medical technology market. This year’s competition drew a record number of submissions from more than 18 countries.

AccurECG is a device-agnostic, FDA-cleared software platform that delivers fully automated, near real-time beat-by-beat ECG interpretation. It supports multiple types of arrhythmias—including atrial fibrillation and atrial flutter—and integrates with a variety of hardware systems, from short-duration ECGs to multi-day Holter and patch monitors.

“We are grateful to MedTech Breakthrough for recognizing AccurECG as the ‘Best New Technology Solution for ECG,’” said Juan C. Jimenez, co-founder and CEO of AccurKardia. “We will continue to deliver innovative solutions that align with our mission to improve patient outcomes and save lives globally.”

In addition to its flagship AccurECG platform, AccurKardia has received two FDA Breakthrough Device Designations in 2024 for AI-powered tools: AK-AVS, which detects moderate to severe aortic valve stenosis, and AK+ Guard, a wearable-compatible algorithm that screens for hyperkalemia—a potentially fatal buildup of potassium in the blood.

“By pioneering these breakthrough ECG-based solutions, AccurKardia is redefining cardiac diagnostics—making them more accessible, actionable, and predictive,” said Steve Johansson, managing director of MedTech Breakthrough.

AccurKardia’s tools are part of a growing trend toward AI-enabled cardiac diagnostics, aimed at improving early detection and intervention for life-threatening conditions.

Howdigital advancements reshape cardiac diagnostics

In recent years, digital innovation has transformed the field of cardiac diagnostics, particularly in the use of electrocardiograms. Traditionally, ECG interpretation required manual review by trained specialists—a time-consuming process with the potential for human error. Now, the integration of artificial intelligence (AI), cloud computing, and real-time data analytics is enabling faster, more accurate, and more scalable ECG-based diagnostics.

One of the most significant shifts is the movement from static, point-in-time ECG readings to continuous or near real-time monitoring. AI-driven platforms like AccurKardia’s AccurECG analyze ECG signals beat-by-beat and can detect arrhythmias such as atrial fibrillation, atrial flutter, and other critical cardiac events without human input. These tools not only speed up diagnosis but can be embedded into a variety of settings—including wearable devices, hospital systems, and remote monitoring platforms.

Another major development is the rise of device-agnostic solutions. New software platforms are designed to integrate seamlessly with a wide range of hardware, from single-lead smartwatches to 12-lead Holter monitors, enhancing flexibility for clinicians and patients alike.

At the frontier of innovation, companies are also using ECG data to detect conditions beyond arrhythmias. AI models are being trained to recognize subtle ECG patterns associated with aortic valve stenosis, hyperkalemia, and even heart failure risk—conditions that previously required imaging or blood tests to identify.

As the sector matures, experts anticipate even broader adoption of AI-powered ECG technologies across primary care, emergency medicine, and at-home monitoring—enabling earlier interventions and improving outcomes for millions at risk of cardiovascular disease.